very-low-dose pegylated interferon α2a plus ribavirin therapy for advanced liver cirrhosis type c: a possible therapeutic alternative without splenic intervention

Clics: 343
ID: 240181
2010
PDF Gratuito
Metricas de Calidad y Rendimiento del Articulo
Calidad General
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
Evaluacion de Calidad por IA
No analizado
Readership in this journal
Popular

Ranked #6 of 54 articles by views in trends in genetics : tig

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Resumen
Despite the recent progress in interferon (IFN) therapies for chronic hepatitis C, liver cirrhosis remains refractory. One of the major obstacles to successful IFN therapy is low platelet count. Currently, splenic interventions, such as partial splenic embolization (PSE) or surgical splenectomy, have been applied effectively and make standard IFN therapy possible. However, there may be a group of patients with low platelet counts who can be treated without splenic intervention. We here report two patients with advanced type C liver cirrhosis who were successfully treated using very-low-dose pegylated interferon α2a plus ribavirin. One patient had a very low platelet count (2.5 × 104/µl) due to splenomegaly before treatment. However, pretreatment serum HCV titers were low in both patients and early viral responses were obtained in both. Because PSE or splenectomy may still have some safety concerns, this attenuated IFN treatment protocol can be an alternative therapeutic option for patients with advanced type C liver disease, but good virological factors for sustained virological response.
Clave de Referencia
ohkoshi2010casevery-low-dose Use esta clave para autocitar en el manuscrito mientras usa SciMatic Manuscript Manager o Thesis Manager
Autores ;Shogo Ohkoshi;Satoshi Yamagiwa;Masahiko Yano;Hiromichi Takahashi;Yo-hei Aoki;Yasunobu Matsuda;Yutaka Aoyagi
Revista trends in genetics : tig
Ano 2010
DOI
10.1159/000318742
URL
http://www.karger.com/Article/FullText/318742
Palabras Clave
ribavirin Gastroenterology avoiding splenic interventiondiseases of the digestive system

Citas

No se encontraron citas. Para agregar una cita, contacte al administrador en info@scimatic.org

Comentarios

Aun no hay comentarios. Sea el primero en comentar este articulo.